JYB-1904 (RPT-904): A Strategic Analysis of a Second-Generation Anti-IgE Monoclonal Antibody

1.0 Executive Summary

1.1 Overview

JYB-1904 is a next-generation, recombinant humanized anti-immunoglobulin E (IgE) monoclonal antibody of the IgG1 subtype, currently in Phase II clinical development. It has been strategically engineered as a "biobetter" to omalizumab (Xolair®), the first-in-class and commercially successful anti-IgE therapy approved for multiple allergic diseases.[1] The core value proposition of JYB-1904 is centered on overcoming the known limitations of omalizumab by incorporating specific molecular enhancements. These modifications are designed to deliver a superior pharmacokinetic and pharmacodynamic profile, characterized by a significantly extended serum half-life, which enables less frequent subcutaneous dosing, and enhanced potency in neutralizing free IgE.[1] This profile positions JYB-1904 to offer improved patient convenience, adherence, and potentially enhanced clinical efficacy, addressing key unmet needs in the management of IgE-mediated conditions.

1.2 Key Findings

The foundational first-in-human Phase Ia clinical trial (NCT05449535) provided robust, positive data that validates the preclinical engineering rationale. In this single ascending-dose study in healthy participants, JYB-1904 was demonstrated to be safe and well-tolerated across all dose levels, with no serious adverse events and a safety profile comparable to that of omalizumab.[1] The risk of immunogenicity was assessed as low, a critical finding for a biologic therapy intended for chronic use.[1] Pharmacokinetic analysis revealed approximately dose-proportional exposure and, most critically, a terminal half-life approximately 2.5 times longer than that of omalizumab at an equivalent dose.[1] This was complemented by pharmacodynamic data showing that JYB-1904 induced a deeper and more sustained suppression of free IgE levels than omalizumab, indicating superior biological activity.[1]

1.3 Clinical and Commercial Strategy

The global development of JYB-1904 is being executed through a strategic partnership between its originator, Jemincare Pharmaceutical Group, and RAPT Therapeutics, Inc..[5] This collaboration employs a dual-track, geographically bifurcated strategy. Jemincare is advancing the clinical program in Greater China, conducting Phase II trials in the established indications of allergic asthma (NCT06438757) and chronic spontaneous urticaria (CSU) (NCT06509334).[5] Concurrently, RAPT Therapeutics has secured the development and commercialization rights for the rest of the world and has designated the molecule RPT-904. RAPT is strategically focusing its initial efforts on the high-growth, high-unmet-need indication of food allergy, with plans to initiate a pivotal Phase IIb trial in the United States and Europe in the second half of 2025.[2]

1.4 Strategic Outlook

JYB-1904 is strongly positioned to potentially become a best-in-class anti-IgE therapy. Its primary path to market disruption is not through a novel mechanism of action, but through the targeted optimization of a clinically and commercially validated one. By leveraging its superior pharmacokinetic profile to offer a more convenient dosing regimen (e.g., every 8 or 12 weeks versus every 2 or 4 weeks for omalizumab), JYB-1904 directly addresses the principal burdens of compliance and convenience for patients on long-term therapy.[2] Furthermore, its enhanced potency may allow for the effective treatment of patients who are currently ineligible for or sub-optimally responsive to omalizumab due to high body weight or baseline IgE levels, thereby expanding the addressable patient population.[2] The combination of a de-risked biological target, compelling early clinical data, a robust global development strategy, and long-term patent protection positions JYB-1904 as a significant future competitor in the multi-billion-dollar market for allergic and inflammatory diseases.

2.0 Molecular Design and Preclinical Rationale: Engineering a Superior Omalizumab

2.1 Foundational Mechanism: The Central Role of IgE in Allergic Disease

The therapeutic rationale for JYB-1904 is built upon the well-established and central role of immunoglobulin E (IgE) in the pathophysiology of Type 1 hypersensitivity reactions, which underpin a range of allergic diseases. In susceptible individuals, exposure to allergens triggers a helper T lymphocyte 2 (Th2)-mediated immune response, leading to the production of allergen-specific IgE antibodies.[1] This IgE circulates and binds with high affinity to its receptor, Fc-epsilon RI (), which is predominantly expressed on the surface of mast cells and basophils.[1] This binding process sensitizes these effector cells. Upon subsequent allergen exposure, the allergen cross-links the receptor-bound IgE molecules, triggering a signaling cascade that results in the rapid degranulation of the cells and the release of a potent cocktail of pre-formed and newly synthesized inflammatory mediators, including histamine, leukotrienes, and cytokines.[8] This inflammatory cascade is directly responsible for the clinical manifestations of allergic diseases, such as bronchoconstriction in asthma, wheal-and-flare reactions in urticaria, and systemic symptoms in food-induced anaphylaxis.[1]

Omalizumab was the first therapeutic agent designed to specifically intercept this pathway. As a humanized IgG1 monoclonal antibody, it binds to the constant region ( domain) of free IgE in the circulation.[8] This action prevents IgE from binding to the  receptor on mast cells and basophils, effectively rendering the IgE inert and pre-empting the cellular activation and degranulation cascade.[1] The subsequent reduction in serum free IgE levels leads to a downregulation of  receptor expression on effector cells, further desensitizing the allergic response over time.[1] The clinical and commercial success of omalizumab has provided unequivocal validation of IgE as a therapeutic target, thereby creating a significantly de-risked biological foundation for the development of next-generation anti-IgE therapies like JYB-1904.

2.2 Strategic Molecular Enhancements of JYB-1904

The development of JYB-1904 represents a classic "biobetter" strategy, which involves taking a proven biologic and applying targeted protein engineering to improve its therapeutic characteristics. Jemincare systematically addressed the known liabilities of omalizumab through several deliberate molecular modifications.[1]

2.2.1 Stability and Manufacturability

A key challenge in the long-term stability and large-scale manufacturing of monoclonal antibodies is chemical degradation, particularly aspartic acid isomerization. Omalizumab contains two known isomerization hotspots within its complementarity-determining regions (CDRs)—the hypervariable loops responsible for antigen binding.[1] These sites can undergo spontaneous chemical changes over time, potentially impacting the antibody's binding affinity and overall integrity. To mitigate this, these two hotspots were engineered out of the JYB-1904 sequence, a modification designed to enhance the antibody's intrinsic stability, improve its shelf-life, and ensure greater consistency during commercial-scale manufacturing.[1]

2.2.2 Reduced Immunogenicity

Omalizumab is a humanized antibody, meaning it originated as a murine antibody whose framework regions were largely replaced with human sequences to reduce the likelihood of an immune reaction in patients. However, it still contains approximately 5% murine-derived amino acid sequences.[8] These non-human sequences carry a residual risk of being recognized as foreign by the patient's immune system, potentially leading to the formation of anti-drug antibodies (ADAs). To further reduce this risk, JYB-1904 underwent additional humanization, whereby several of the remaining murine amino acids in the framework region were replaced with human counterparts. This modification was intended to lower the potential for immunogenicity, thereby improving the long-term safety and tolerability profile of the drug.[1]

2.2.3 Enhanced Potency and Affinity

To improve upon the biological activity of omalizumab, JYB-1904 was subjected to affinity maturation using a yeast surface display platform.[1] This powerful screening technology allows for the rapid testing of millions of antibody variants to identify those with the highest binding affinity for the target antigen, in this case, human IgE. This process resulted in the selection of a candidate with an enhanced ability to bind to and neutralize free IgE.[8] Preclinical binding studies later confirmed that JYB-1904 demonstrated an increased affinity for free human IgE compared to omalizumab.[9] This higher affinity translates directly to greater potency, suggesting that JYB-1904 can achieve a more profound biological effect at equivalent or lower doses.

2.2.4 Extended Serum Half-Life

The most strategically significant modification made to JYB-1904 was the introduction of the "YTE" mutation (M252Y/S254T/T256E) into the crystallizable fragment (Fc) region of the antibody.[1] The half-life of IgG antibodies in circulation is regulated by the neonatal Fc receptor (FcRn), a cellular receptor that acts as a salvage mechanism, protecting IgG from lysosomal degradation.[9] The YTE mutation has been well-characterized to increase the binding affinity of the IgG Fc region to FcRn, particularly at the acidic pH found within endosomes. This enhanced binding leads to more efficient recycling of the antibody back into circulation, thereby significantly extending its serum half-life.[9] This single engineering choice is the cornerstone of JYB-1904's primary clinical differentiator: the potential for a substantially less frequent dosing schedule.

2.3 Summary of Preclinical Superiority

The culmination of these molecular engineering efforts was a preclinical candidate that demonstrated clear advantages over omalizumab. In a suite of in vitro and in vivo preclinical studies, JYB-1904 exhibited desirable biophysical properties, improved chemical stability, enhanced efficacy in neutralizing IgE, and, critically, a prolonged serum half-life.[1] These superior preclinical properties provided a robust and compelling scientific rationale for advancing JYB-1904 into human clinical trials, with the clear objective of confirming these benefits and establishing a new standard of care in anti-IgE therapy.[1]

The entire preclinical development program for JYB-1904 was not an exercise in novel target discovery but a highly focused effort of targeted optimization. By starting with the known biological mechanism and molecular structure of omalizumab, the developers could systematically identify and address its specific shortcomings. The removal of isomerization hotspots directly targets stability, the further humanization targets immunogenicity, the affinity maturation targets potency, and the YTE mutation targets half-life. This incremental, engineering-driven approach represents a significantly de-risked development pathway compared to programs for novel biologics, as the fundamental question of whether the mechanism of action is valid has already been answered affirmatively by the clinical and commercial history of omalizumab.

3.0 Clinical Pharmacology: Evidence from the First-in-Human Study

3.1 Study Design: Phase Ia (NCT05449535)

The first-in-human evaluation of JYB-1904 was conducted in a Phase Ia trial (NCT05449535), which began in May 2022 and was completed in January 2023.[10] The study was designed as a single-center, randomized, double-blind, placebo-controlled, single ascending-dose trial conducted in 56 healthy adult Chinese participants.[1] Its primary objectives were to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of JYB-1904.[1]

The study employed a dose-escalation design, evaluating five sequential dose levels of JYB-1904 administered via subcutaneous injection, ranging from 75 mg to 600 mg.[3] A strategically critical feature of the trial design was the inclusion of an active comparator arm, in which a cohort of participants received a single dose of omalizumab (Xolair).[10] The inclusion of this active comparator, while not standard for all first-in-human studies, was a pivotal decision. It allowed for a direct, head-to-head comparison of the pharmacological properties of JYB-1904 and omalizumab within the same controlled study environment. This approach provides invaluable early comparative data, enabling a much more robust assessment of the "biobetter" hypothesis and significantly de-risking subsequent development decisions.

3.2 Pharmacokinetic (PK) Profile: Demonstrating a Longer Half-Life

The pharmacokinetic analysis from the Phase Ia study yielded highly favorable results that directly validated the preclinical engineering strategy. The exposure to JYB-1904, as measured by maximum serum concentration () and area under the concentration-time curve (AUC), increased in an approximately dose-proportional manner across the 75 mg to 600 mg range.[1] This predictability is a desirable characteristic for any new therapeutic, as it simplifies dose selection for later-stage trials.

The most significant PK finding was the confirmation of a substantially extended serum half-life. The median terminal half-life of JYB-1904 was found to be more than two times, and specifically 2.5 times, that of omalizumab when compared at an equivalent dose level.[1] Investor materials from RAPT Therapeutics provide more granular detail, reporting a median half-life of 63 days for JYB-1904 at the 150 mg dose, compared to just 27 days for omalizumab at the same dose.[2] This clinical result serves as definitive proof-of-concept for the YTE mutation, demonstrating that the enhanced binding to the FcRn salvage receptor successfully translated from preclinical models to a prolonged duration of action in humans. This single data point is the bedrock of the entire commercial and clinical strategy for JYB-1904, as it provides the quantitative evidence to support the primary value proposition of a less frequent dosing regimen.

3.3 Pharmacodynamic (PD) Profile: Superior IgE Suppression

The pharmacodynamic results, which measure the drug's direct biological effect on its target, were equally compelling. JYB-1904 demonstrated a significantly stronger and more sustained suppression of free IgE levels in the serum compared to omalizumab at the same dose.[1] The data showed not only a deeper nadir in free IgE but also a longer duration of suppression, which is consistent with the extended pharmacokinetic half-life.[11] This superior PD activity suggests that JYB-1904 is not only longer-acting but also possesses greater potency in neutralizing its target. This enhanced biological activity could potentially translate into improved clinical efficacy, faster onset of action, or effective treatment for patients with higher baseline IgE levels who may be sub-optimally responsive to omalizumab.

3.4 Safety, Tolerability, and Immunogenicity

Across all five ascending-dose cohorts, a single subcutaneous dose of JYB-1904 was found to be safe and well-tolerated.[1] There were no serious adverse events (SAEs) or dose-limiting toxicities reported in any participant receiving JYB-1904.[1] All treatment-related adverse events were classified as mild (Grade 1 or 2) in severity, and the overall safety profile was comparable to that observed in the omalizumab and placebo arms, with no new or unexpected safety signals emerging.[6]

A critical secondary endpoint was the assessment of immunogenicity. The development of anti-drug antibodies (ADAs) can neutralize the therapeutic effect of a biologic and, in some cases, lead to adverse events. The analysis from the Phase Ia study indicated a low risk of immunogenicity for JYB-1904.[1] This finding suggests that the molecular engineering efforts to further humanize the antibody framework and remove murine sequences were successful in minimizing its recognition by the human immune system. A low immunogenicity profile is essential for a therapy intended for chronic administration in the treatment of allergic diseases.

4.0 Clinical Development Program and Therapeutic Applications

The clinical development of JYB-1904 is advancing through a coordinated, multi-indication, global program managed by Jemincare in Greater China and RAPT Therapeutics in the rest of the world. This bifurcated strategy allows for parallel progress in several key allergic diseases, efficiently generating a broad dataset to support future regulatory submissions.

Trial Identifier	Internal ID	Phase	Indication	Status	Patient Population	# of Subjects	Sponsor	Key Objectives
NCT05449535	JY20210115-Ia	Ia	Healthy Volunteers	Completed	Healthy Chinese Adults	56	Jemincare	Evaluate safety, tolerability, PK, PD, and immunogenicity of single ascending doses.
NCT06438757	JYB1904-201	IIa	Allergic Asthma	Active, Not Recruiting	Adults (18-75 years) with allergic asthma.	69	Jemincare	Evaluate PK, PD, and safety in patients to inform Phase III dosing.
NCT06509334	JYB1904-202	II	Chronic Spontaneous Urticaria (CSU)	Recruiting	Adults (≥18 years) with CSU refractory to antihistamines.	135	Jemincare	Evaluate efficacy, safety, and tolerability in patients with CSU.
Planned	TBD	IIb	Food Allergy	Planned (2H 2025 Start)	Children and adults with documented food allergies.	~75	RAPT Therapeutics	Evaluate efficacy of Q8W and Q12W dosing regimens vs. placebo.

4.1 Allergic Asthma Program (Led by Jemincare in China)

Jemincare is conducting a Phase IIa clinical trial (NCT06438757, JYB1904-201) to evaluate JYB-1904 in patients with allergic asthma.[13] This study has enrolled 69 adult patients aged 18 to 75 years.[13] The primary objective of this trial is not to serve as a pivotal efficacy study, but rather to assess the pharmacokinetics, pharmacodynamics, and safety of JYB-1904 in a patient population, as opposed to the healthy volunteers in the Phase Ia study.[5] The data gathered will be crucial for informing the optimal dose selection for a potential future Phase III registrational trial.[5] The study design continues the strategically valuable head-to-head comparison approach, incorporating three different dose levels of JYB-1904 alongside an active omalizumab comparator arm.[13] Topline data from this important study are anticipated in the second half of 2025.[2]

4.2 Chronic Spontaneous Urticaria (CSU) Program (Led by Jemincare in China)

In parallel, Jemincare is advancing a Phase II trial (NCT06509334, JYB1904-202) in patients with chronic spontaneous urticaria.[14] This study is designed to enroll 135 adult patients with CSU who have had an inadequate response to second-generation H1-antihistamines, the first-line standard of care.[14] Unlike the asthma study, the primary objective here is to evaluate the clinical efficacy, safety, and tolerability of JYB-1904 in this indication.[14] The trial is designed with two dose levels of JYB-1904 and an active omalizumab comparator arm.[16] Key eligibility criteria include a diagnosis of CSU for at least three months and a baseline Urticaria Activity Score over 7 days (UAS7) of 16 or greater, indicating moderate-to-severe disease activity.[14] Notably, patients with a history of poor efficacy with omalizumab are excluded, ensuring the study population is representative of patients who would be candidates for anti-IgE therapy.[14] Topline results from this efficacy-focused trial are expected in the first half of 2026.[2]

4.3 Food Allergy Program (Led by RAPT Therapeutics, Rest-of-World)

RAPT Therapeutics has strategically selected food allergy as its lead indication for development in the major commercial markets of the United States and Europe.[5] This decision is underpinned by a clear market opportunity. The recent FDA approval of omalizumab for reducing allergic reactions to multiple foods has validated the anti-IgE mechanism in this setting and has been met with rapid uptake by physicians and patients, confirming a significant unmet need for effective therapies beyond simple allergen avoidance.[2] This has effectively "primed" the market, creating established clinical and reimbursement pathways that a second-generation agent can leverage. RAPT is positioned to enter this nascent market not as a "me-too" product, but as a "biobetter" that directly addresses the primary inconvenience of the incumbent therapy—frequent injections—a particularly salient issue for pediatric patients and their caregivers.

RAPT plans to initiate a Phase IIb clinical trial in food allergy in the second half of 2025.[5] The proposed study is a randomized, double-blind, placebo-controlled trial designed to evaluate both 8-week (Q8W) and 12-week (Q12W) subcutaneous dosing regimens of RPT-904 in children and adults.[17] The primary endpoint will be a rigorous assessment of efficacy via a Double-Blind, Placebo-Controlled Food Challenge (DBPCFC), the gold standard for diagnosing food allergy and measuring therapeutic response.[17] A key strategic element of RAPT's development plan is the intention to enroll patients who are currently excluded from the omalizumab label due to high body weight or high baseline IgE levels.[2] Success in this expanded population would not only provide a key point of differentiation but would also significantly broaden the total addressable market for the drug.

The overall development program represents a sophisticated and risk-mitigated global strategy. Jemincare's work in China in the well-established indications of asthma and CSU serves to build a substantial safety and efficacy database, which will be invaluable for all future regulatory filings worldwide. This de-risks the asset globally. RAPT can then leverage this growing body of data to support its pursuit of the higher-reward expansion indication of food allergy in the lucrative US and EU markets. The staggered timelines, with data from Jemincare's trials expected before the completion of RAPT's Phase IIb study, mean that RAPT will be able to proceed with its later-stage development and regulatory interactions armed with a much more comprehensive data package than would typically be available for an asset at a similar stage.

5.0 Regulatory Status and Pathway

As an investigational therapeutic, JYB-1904 (RPT-904) has not yet received marketing approval from any global regulatory authority and remains in Phase II clinical development.[4] The regulatory strategy is aligned with the territorial rights established in the Jemincare-RAPT partnership, with parallel pathways being pursued in China, the United States, and Europe.

5.1 U.S. Food and Drug Administration (FDA) Pathway

RAPT Therapeutics is leading the regulatory engagement in the United States. The company plans to file its first Investigational New Drug (IND) application with the FDA for RPT-904 in the first half of 2025.[2] This submission will enable the initiation of the planned Phase IIb clinical trial in food allergy, which will be conducted at sites in the U.S. and Europe.[17] The development program is clearly oriented towards the U.S. market, which represents the largest commercial opportunity for this class of drugs.[17]

5.2 European Medicines Agency (EMA) Pathway

For marketing authorization in the European Union, JYB-1904, as a medicinal product derived from biotechnology, will be required to follow the Centralized Procedure.[9] This procedure involves a single application submitted to the European Medicines Agency (EMA). A positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) would then lead to a single marketing authorization granted by the European Commission, which is valid in all EU member states as well as in the European Economic Area (EEA) countries.[9] RAPT Therapeutics holds the development and commercialization rights for these territories and will be responsible for pursuing this regulatory pathway.[19]

5.3 China National Medical Products Administration (NMPA) Pathway

All clinical development activities within Greater China are under the purview of the originator, Jemincare. The initial Phase Ia first-in-human study (registered as CTR20220973 with the NMPA) was conducted in China, as are the ongoing Phase II trials in allergic asthma (NCT06438757) and chronic spontaneous urticaria (NCT06509334).[10] Jemincare will be responsible for compiling the clinical data from these trials into a marketing application for submission to the China National Medical Products Administration (NMPA) to seek approval in its retained territories.[5]

The global regulatory strategy effectively mirrors the commercial and development strategy. Jemincare is responsible for generating the core clinical data package required for approval in China. RAPT will then leverage this foundational data, supplement it with results from its own global trials (such as the planned food allergy study), and submit comprehensive dossiers to the FDA and EMA. This coordinated, parallel approach is highly efficient, allowing for the sharing of data and regulatory learnings between the partners to streamline and strengthen the submissions in each major pharmaceutical market.

6.0 Strategic Analysis: Market Positioning and Corporate Development

6.1 Competitive Differentiation and Value Proposition

JYB-1904 is positioned not as a disruptive new entrant with an unproven mechanism, but as a strategically enhanced successor to an established blockbuster. Its value proposition is centered on being a "best-in-class" anti-IgE therapy that offers tangible clinical and practical advantages over the first-generation standard of care, omalizumab. The competitive differentiation is a direct result of the molecular engineering embedded in its design.

The most significant advantage is the potential for a substantially more convenient dosing schedule. The clinically confirmed 2.5-fold longer half-life supports a projected dosing interval of every 8 to 12 weeks (Q8W/Q12W), a marked improvement over the every 2 to 4 week (Q2W/Q4W) regimen required for omalizumab.[2] For patients with chronic allergic diseases, this reduction in treatment burden—from 13-26 injections per year to just 4-6—represents a major improvement in quality of life and is expected to drive superior long-term adherence. This is further enhanced by the potential for a broader therapeutic window. The superior IgE suppression observed in the Phase Ia study suggests that JYB-1904 may offer greater efficacy or be effective in patients with high body weight or high baseline IgE levels who fall outside the approved dosing parameters for omalizumab, thereby expanding the treatable patient population.[1] Finally, JYB-1904 is protected by a composition of matter patent extending to 2041, providing a long period of market exclusivity that will shield it from the pricing pressures of omalizumab biosimilars that are expected to enter the market.[2]

Feature	JYB-1904 (RPT-904)	Omalizumab (Xolair®)
Target	Immunoglobulin E (IgE)	Immunoglobulin E (IgE)
Mechanism of Action	Binds free IgE, preventing interaction with	Binds free IgE, preventing interaction with
Molecular Subtype	Humanized IgG1 Monoclonal Antibody	Humanized IgG1 Monoclonal Antibody
Key Engineering Modifications	YTE mutation for half-life extension; Affinity maturation; Isomerization hotspot removal; Further humanization	Original humanized sequence
Serum Half-Life (Clinical Data)	~63 days (at 150 mg)	~27 days (at 150 mg)
Dosing Frequency (Projected)	Every 8-12 weeks (Q8W/Q12W)	Every 2-4 weeks (Q2W/Q4W)
Pharmacodynamic Effect	Deeper and more sustained free IgE suppression	Standard free IgE suppression
Potential Patient Population	Standard population + potential for high weight/high IgE patients	Restricted by weight/IgE dosing tables
Patent Exclusivity (Composition)	Expected until 2041	Facing loss of exclusivity and biosimilar competition

6.2 The Jemincare-RAPT Therapeutics Licensing Agreement

In December 2024, the strategic partnership that will guide JYB-1904's global trajectory was formalized.[5] The agreement was executed between the originator, Shanghai Jemincare Pharmaceutical Co., Ltd. (a subsidiary of Jiangxi Jemincare Group), and RAPT Therapeutics, Inc., a U.S.-based clinical-stage biopharmaceutical company specializing in immunology.[5]

Under the terms of the exclusive license agreement, RAPT Therapeutics acquired the worldwide rights to develop and commercialize the drug, which it has designated RPT-904. Jemincare retains the rights for its home territory, defined as mainland China, Hong Kong, Macau, and Taiwan.[5] The financial terms of the deal are substantial and reflect a high degree of confidence in the asset's potential. RAPT made an upfront payment of $35 million to Jemincare. In addition, Jemincare is eligible to receive up to $672.5 million in further payments tied to the achievement of specific regulatory and commercial milestones. Finally, Jemincare will receive tiered royalties on future net sales of the product in RAPT's territories, reported to be in the high-single-digit to low-double-digit range.[2] A $35 million upfront payment for an asset with only Phase I data is a significant financial commitment and serves as a strong external validation of the quality of the data and the perceived probability of clinical and commercial success.

6.3 Market Opportunity and Future Outlook

The commercial opportunity for a best-in-class anti-IgE therapy is substantial. Omalizumab has established a multi-billion-dollar global market across its approved indications of allergic asthma and CSU. The recent expansion into food allergy has opened a significant new growth vector, with its rapid market uptake demonstrating a high level of unmet need that JYB-1904 is ideally positioned to address with a more convenient product profile.[2]

The development program has several key catalysts on the horizon that will be critical in shaping the future of JYB-1904. The first major data readouts from patient populations are expected in the second half of 2025, with the topline results from Jemincare's Phase IIa trial in allergic asthma. This will be followed by the results from the Phase II CSU trial in the first half of 2026. These two datasets will provide the first clear look at the drug's efficacy and safety profile in its intended patient populations. Subsequently, the topline data from RAPT's Phase IIb trial in food allergy, expected in the first half of 2027, will be a pivotal event, as it will define the drug's potential in its lead ex-China indication.[2] Positive outcomes from these trials would pave the way for Phase III registrational studies and eventual marketing applications in the world's largest pharmaceutical markets.

7.0 Appendix: Standard of Care in Target Indications

7.1 Allergic Asthma

The management of allergic asthma follows a stepwise approach outlined by global guidelines such as the Global Initiative for Asthma (GINA) and the U.S. National Heart, Lung, and Blood Institute (NHLBI).[22] Treatment for mild, intermittent asthma begins with as-needed short-acting beta2-agonists (SABAs). For persistent asthma, the cornerstone of therapy is daily inhaled corticosteroids (ICS) to control airway inflammation.[22] As disease severity increases, treatment is intensified by adding a long-acting beta2-agonist (LABA) to the ICS, often in a combination inhaler.[22] For patients who remain uncontrolled, options include increasing the ICS dose or adding a long-acting muscarinic antagonist (LAMA).[22] For patients with moderate-to-severe allergic asthma that is not adequately controlled by these therapies, add-on biologic treatments are recommended. This is where anti-IgE therapy (omalizumab) is positioned, alongside other biologics that target different aspects of the Th2 inflammatory pathway, such as anti-IL-5/IL-5R and anti-IL-4Rα antibodies.[1]

7.2 Chronic Spontaneous Urticaria (CSU)

International guidelines for the management of CSU also follow a stepwise algorithm.[28] The first-line treatment consists of second-generation, non-sedating H1-antihistamines at standard doses.[31] If symptoms are not controlled after 2-4 weeks, the recommended second step is to increase the dose of the antihistamine, up to four times the standard licensed dose.[28] For the significant proportion of patients whose urticaria remains active despite high-dose antihistamines, the third-line treatment is the addition of omalizumab.[28] Omalizumab has demonstrated high efficacy in this antihistamine-refractory population. For the small number of patients who do not respond adequately to omalizumab, the fourth-line option is the immunosuppressant cyclosporine, though its use is limited by potential side effects.[28] Short courses of oral corticosteroids may be used to manage severe exacerbations but are not recommended for long-term control.[28]

7.3 Food Allergy

The current standard of care for the management of food allergy has historically been centered on three core principles: strict dietary avoidance of the known allergenic food, education on label reading and cross-contact prevention, and the provision of an emergency action plan for the management of accidental exposures.[33] The cornerstone of emergency treatment is the prompt administration of intramuscular epinephrine for any signs of a systemic allergic reaction (anaphylaxis).[34] Until recently, no approved therapies existed to modify the underlying allergic response. The 2024 FDA approval of omalizumab for the reduction of allergic reactions that may occur with accidental exposure to one or more foods represents a paradigm shift in the management of food allergy.[2] It is the first and only approved therapy for this indication, moving the field beyond avoidance and emergency treatment toward proactive, long-term management to increase the threshold for reaction and reduce the risk of severe outcomes from accidental exposures.[37]

Works cited

1. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study - PMC, accessed October 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12160614/
2. Transforming the Treatment of Cancer and Inflammation, accessed October 9, 2025, https://investors.rapt.com/static-files/48e058d4-c59f-4ce1-8979-c4d7d0884580
3. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single-Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double-Blind, Placebo-Controlled Study - PubMed, accessed October 9, 2025, https://pubmed.ncbi.nlm.nih.gov/40504164/
4. JYB-1904 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 9, 2025, https://synapse.patsnap.com/drug/415b8439c5ad42f49a6fcf67cb5200fc
5. RAPT and Jemincare Announce License for New Long-Acting anti-IgE Antibody, accessed October 9, 2025, https://synapse.patsnap.com/article/rapt-and-jemincare-announce-license-for-new-long-acting-anti-ige-antibody
6. RAPT Therapeutics and Shanghai Jemincare Pharmaceutical, accessed October 9, 2025, https://www.globenewswire.com/news-release/2024/12/23/3001125/0/en/RAPT-Therapeutics-and-Shanghai-Jemincare-Pharmaceutical-Announce-Exclusive-License-Agreement-for-Novel-Long-Acting-anti-IgE-Antibody.html
7. RAPT takes aim at Xolair's food allergy breakthrough via deal with Jemincare, accessed October 9, 2025, https://firstwordpharma.com/story/5923240
8. An Omalizumab Biobetter Antibody (JYB1904) With Improved Stability and Efficacy For The Treatment of Allergic Diseases | PDF | Allergy - Scribd, accessed October 9, 2025, https://www.scribd.com/document/830523773/An-Omalizumab-Biobetter-Antibody-JYB1904-With-Improved-Stability-and-Efficacy-for-the-Treatment-of-Allergic-Diseases
9. 10-K - SEC.gov, accessed October 9, 2025, https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm
10. Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects - ICH GCP, accessed October 9, 2025, https://ichgcp.net/clinical-trials-registry/NCT05449535
11. Form 8-K for Rapt Therapeutics INC filed 12/23/2024, accessed October 9, 2025, https://investors.rapt.com/static-files/ab7730a0-afe0-46e8-9a47-498d3f058d80
12. RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - SEC.gov, accessed October 9, 2025, https://www.sec.gov/Archives/edgar/data/1673772/000119312524283668/d926285dex991.htm
13. Trial of JYB1904 in Patients With Allergic Asthma, accessed October 9, 2025, https://ctv.veeva.com/study/phase-iia-trial-of-jyb1904-in-patients-with-allergic-asthma
14. Trial of JYB1904 in Chronic Spontaneous Urticaria. | Clinical Research Trial Listing, accessed October 9, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06509334/trial-of-jyb1904-in-chronic-spontaneous-urticaria
15. Trial of JYB1904 in Chronic Spontaneous Urticaria. - ClinConnect, accessed October 9, 2025, https://clinconnect.io/trials/NCT06509334
16. Trial of JYB1904 in Chronic Spontaneous Urticaria. - ClinicalTrials.Veeva, accessed October 9, 2025, https://ctv.veeva.com/study/trial-of-jyb1904-in-chronic-spontaneous-urticaria
17. EX-99.3 - SEC.gov, accessed October 9, 2025, https://www.sec.gov/Archives/edgar/data/1673772/000119312524283668/d926285dex993.htm
18. Likelihood of Approval and Phase Transition Success Rate Model - JYB-1904 in Chronic Urticaria Or Hives - Market Research Reports & Consulting - GlobalData, accessed October 9, 2025, https://www.globaldata.com/store/report/jyb-1904-in-chronic-urticaria-or-hives-loa-innovation-and-trend-analysis/
19. RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - Stock Titan, accessed October 9, 2025, https://www.stocktitan.net/news/RAPT/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-announce-6nfoo8j5igw2.html
20. RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody, accessed October 9, 2025, https://rapt.com/news/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-announce-exclusive-license-agreement-for-novel-long-acting-anti-ige-antibody/
21. Exclusive License Agreement between Shanghai Jemincare Pharmaceutical Co., Ltd. and RAPT Therapeutics, Inc. (JYB1904) - Business Contracts | Justia, accessed October 9, 2025, https://contracts.justia.com/companies/rapt-therapeutics-inc-9017/contract/1307170/
22. 2020 Focused Updates to the Asthma Management Guidelines: Clinician's Guide - Bronson Healthcare, accessed October 9, 2025, https://www.bronsonhealth.com/app/files/public/6e04d14b-7228-4406-9a8e-8f6ee83b6d28/CPG/Focused_Updates_to_Asthma_Management_Guidelines_Clinicians_Guide.pdf
23. Asthma Care Quick Reference - nhlbi, nih, accessed October 9, 2025, https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf
24. GINA Pocket Guide 2023 - Global Initiative for Asthma, accessed October 9, 2025, https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Pocket-Guide-WMS.pdf
25. Asthma Management: Updated Guidelines from the National Heart, Lung, and Blood Institute | AAFP, accessed October 9, 2025, https://www.aafp.org/pubs/afp/issues/2021/1100/p531.html
26. 2020 Focused Updates to the Asthma Management Guidelines | NHLBI, NIH, accessed October 9, 2025, https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates
27. Asthma - Diagnosis and treatment - Mayo Clinic, accessed October 9, 2025, https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660
28. Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations - PMC, accessed October 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5603475/
29. BSACI guideline for the management of chronic urticaria and angioedema, accessed October 9, 2025, https://www.bsaci.org/wp-content/uploads/2020/01/Urticaria_Angioedema2015-1.pdf
30. ASCIA Chronic Spontaneous Urticaria (CSU) Position Paper and Treatment Guidelines, accessed October 9, 2025, https://www.allergy.org.au/hp/papers/chronic-spontaneous-urticaria-csu-guidelines
31. chronic spontaneous urticaria (chronic ordinary urticaria; chronic idiopathic urticaria) - Primary Care Dermatology Society, accessed October 9, 2025, https://www.pcds.org.uk/clinical-guidance/urticaria-spontaneous-syn-chronic-ordinary-urticaria
32. Acute and Chronic Urticaria: Evaluation and Treatment - AAFP, accessed October 9, 2025, https://www.aafp.org/pubs/afp/issues/2017/0601/p717.html
33. Food Allergies | FDA, accessed October 9, 2025, https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/food-allergies
34. Food Allergies | Causes, Symptoms & Treatment | ACAAI Public Website, accessed October 9, 2025, https://acaai.org/allergies/allergic-conditions/food/
35. Guidelines for the Care of Students with Food Allergies - Texas Department of State Health Services (DSHS), accessed October 9, 2025, https://www.dshs.texas.gov/sites/default/files/schoolhealth/docs/Guidelines%20for%20Food%20Allergies_PublicComment.pdf
36. Food Allergy & Anaphylaxis Emergency Care Plan - FoodAllergy.org, accessed October 9, 2025, https://www.foodallergy.org/living-food-allergy/food-allergy-essentials/food-allergy-anaphylaxis-emergency-care-plan
37. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report - PMC, accessed October 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4241958/
38. CDC National School Food Allergy Guidelines - FoodAllergy.org, accessed October 9, 2025, https://www.foodallergy.org/resources/cdc-national-school-food-allergy-guidelines